News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ALS Biopharma LLC Agreement



10/20/2010 2:53:20 PM

Doylestown, PA. 9/27/2010 – ALS Biopharma, LLC is pleased to announce a strategic alliance with Vybion, a platform biologics development company located in Ithaca, New York. Vybion will provide a license to ALS Biopharma for its patented PEGylation technology for the purpose of preparing novel biologic therapeutics for the treatment of ALS and related neuropathies. Vybion is currently producing modified biologic therapeutics for evaluation by ALS Biopharma. In addition, Lee Henderson, Ph.D., CEO of Vybion, has been appointed to serve on the Scientific Advisory Board of ALS Biopharma.

ALS Biopharma, LLC is an emerging discovery and development phase biopharmaceutical company focused on rapidly bringing a disease modifying biologic therapy to the clinic for the orphan indication of ALS. ALS Biopharma is located at the Pennsylvania Biotechnology Center, a Pennsylvania Keystone Innovation Zone in Bucks County, PA.


Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES